Epoch Investment Partners Inc. Sells 21,197 Shares of IDEXX Laboratories, Inc. $IDXX

Epoch Investment Partners Inc. lessened its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 10.8% during the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 174,602 shares of the company’s stock after selling 21,197 shares during the period. Epoch Investment Partners Inc.’s holdings in IDEXX Laboratories were worth $98,107,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. SHP Wealth Management acquired a new position in IDEXX Laboratories during the 4th quarter worth about $26,000. Virtus Advisers LLC acquired a new stake in IDEXX Laboratories in the 3rd quarter valued at about $26,000. WealthCollab LLC acquired a new stake in IDEXX Laboratories in the 2nd quarter valued at about $30,000. Caitong International Asset Management Co. Ltd bought a new position in shares of IDEXX Laboratories in the third quarter worth about $36,000. Finally, Mowery & Schoenfeld Wealth Management LLC raised its stake in shares of IDEXX Laboratories by 58.8% in the fourth quarter. Mowery & Schoenfeld Wealth Management LLC now owns 54 shares of the company’s stock worth $37,000 after acquiring an additional 20 shares during the last quarter. 87.84% of the stock is currently owned by institutional investors and hedge funds.

IDEXX Laboratories Stock Performance

Shares of IDEXX Laboratories stock opened at $544.32 on Friday. The firm has a fifty day moving average of $556.27 and a two-hundred day moving average of $595.41. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.82 and a current ratio of 1.12. The stock has a market capitalization of $42.94 billion, a price-to-earnings ratio of 40.08, a PEG ratio of 2.95 and a beta of 1.55. IDEXX Laboratories, Inc. has a 52 week low of $518.55 and a 52 week high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings results on Tuesday, May 5th. The company reported $3.47 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.41 by $0.06. The business had revenue of $1.14 billion for the quarter, compared to analyst estimates of $1.12 billion. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The firm’s revenue was up 14.3% on a year-over-year basis. During the same period last year, the company earned $2.91 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. As a group, equities research analysts predict that IDEXX Laboratories, Inc. will post 14.68 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms have recently commented on IDXX. Wall Street Zen cut shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Sunday, July 12th. Stifel Nicolaus reduced their price objective on IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating on the stock in a report on Tuesday, March 31st. Weiss Ratings lowered IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research report on Tuesday, July 14th. UBS Group lowered their target price on IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating for the company in a research note on Tuesday, April 28th. Finally, Citigroup initiated coverage on IDEXX Laboratories in a research note on Wednesday, April 15th. They set a “neutral” rating and a $650.00 price target on the stock. Six equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $751.00.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.